All posts by: Michael Zand

Study of protein cages strengthens Bristol’s position at forefront of synthetic biology
Gears Of Biz
A multidisciplinary team of mathematicians, theoretical physicists, chemists and biochemists from the University of Bristol came together to study the self-assembly of protein building into protein cages with possible applications in nanotechnology and …

Study of protein cages strengthens Bristol’s position at forefront of synthetic biology
Gears Of Biz
A multidisciplinary team of mathematicians, theoretical physicists, chemists and biochemists from the University of Bristol came together to study the self-assembly of protein building into protein cages with possible applications in nanotechnology and …

Antibiotic ineffective at preventing lung complication after stem cell transplant: Study
UPI.com
9, 2017 — An antibiotic treatment intended to lower stem cell transplant patients’ risk of developing a respiratory complication appears to have backfired. French researchers explored the potential of administering the antibiotic azithromycin before …

Pfizer chooses Sanford, North Carolina site for $100m gene therapy plant
BioPharma-Reporter.com
According to North Carolina Governor Roy Cooper, Pfizer will spend $100m (€85m) on the new facility and has also committed $4m to support postdoctoral fellowships in North Carolina universities for training in gene therapy research. The project will …

Amniotic sac in a dish: Stem cells form structures that may aid of infertility research
Science Daily
But scientists haven’t had a good way to explore the biology behind this phenomenon. Now, a new achievement using human stem cells could give researchers a chance to see what they couldn’t before, while avoiding ethical issues associated with studying …

and more »

Pfizer commits $100M for a gene therapies plant in North Carolina
FiercePharma
Pfizer committed to building a $100 million gene therapies plant in North Carolina and in exchange, North Carolina committed to providing the drugmaker with a quarter-million dollars’ worth of help. Pfizer will expand an 11,000-square-foot plant in …

Silverstein-backed startup will test gene therapy for Parkinson’s
FierceBiotech
Regenxbio has joined forces with investment firm OrbiMed and a new nonprofit foundation to create Prevail Therapeutics, a startup focused on new biologics and gene therapies for Parkinson’s disease (PD). Prevail will draw on the expertise of the …
Orbimed partner in search of a cure for Parkinson’s launches new gene therapy playerEndpoints News
For Parkinson’s, Two Drugs Coming And One New Co as Prevail Starts in NYXconomy
The Silverstein Foundation, REGENXBIO, and OrbiMed Launch Prevail TherapeuticsBusiness Wire (press release)
CNBC
all 6 news articles »